Welcome to our dedicated page for Moderna news (Ticker: MRNA), a resource for investors and traders seeking the latest updates and insights on Moderna stock.
Moderna (MRNA) remains at the forefront of mRNA technology innovation, developing transformative therapies for infectious diseases, oncology, and rare conditions. This dedicated news hub provides investors and healthcare professionals with essential updates directly from the company and verified sources.
Access official press releases covering clinical trial results, regulatory milestones, and strategic partnerships, alongside analysis of quarterly earnings and pipeline developments. Our curated collection ensures you stay informed about Moderna's progress in advancing mRNA-based medicines without promotional bias.
Key updates include developments in respiratory vaccines, cancer immunotherapy candidates, and rare disease treatments. Bookmark this page for real-time access to Moderna's verified announcements and objective reporting on one of biotechnology's most innovative platforms.
Moderna (NASDAQ: MRNA) has announced its upcoming participation in two major investor conferences in June 2025. The company will present at the Jefferies Global Health Care Conference on June 5th at 10:30am ET and the Goldman Sachs 46th Annual Global Healthcare Conference on June 11th at 8:40am ET.
Live webcasts of both presentations will be accessible through the "Events and Presentations" section on Moderna's investor website. Replays will remain available for at least 30 days after each presentation.
Moderna (NASDAQ:MRNA) has submitted an FDA application for its updated Spikevax 2025-2026 formula, specifically designed to target the SARS-CoV-2 LP.8.1 variant. The submission aligns with FDA guidance recommending COVID-19 vaccines be updated to a monovalent JN.1 lineage, with preference for the LP.8.1 variant.
Moderna (NASDAQ:MRNA) has voluntarily withdrawn its Biologics License Application (BLA) for mRNA-1083, its combination flu/COVID vaccine candidate for adults aged 50 and older. The withdrawal comes after consultation with the FDA. The company plans to resubmit the BLA later in 2025 after obtaining vaccine efficacy data from the ongoing Phase 3 trial of mRNA-1010, its investigational seasonal influenza vaccine. Interim data from the mRNA-1010 trial is expected to be available in summer 2025.
Cellarity has appointed Ted Myles as its new Chief Executive Officer and CEO-Partner at Flagship Pioneering. Myles brings extensive biopharma leadership experience, previously serving as CFO and COO of Scholar Rock where he raised over $1 billion and led the company through a successful Phase 3 study. His prior roles include executive positions at AMAG Pharmaceuticals, Ocata Therapeutics, and PrimeraDx.
The appointment comes as Cellarity prepares for its first clinical study in 2025. The company leverages an AI/ML-enabled platform for drug discovery, focusing on understanding dysregulated pathways in diseased human cells. Their lead program, CLY-124, is a potential first-in-class small molecule for sickle cell disease treatment, targeting fetal hemoglobin induction through a novel mechanism, with clinical development expected to begin in mid-2025.
Moderna (NASDAQ: MRNA) has announced its upcoming participation in Bernstein's 41st Annual Strategic Decisions Conference (SDC). The presentation is scheduled for Thursday, May 29th, 2025, at 10:00 AM ET. Investors and interested parties can access a live webcast of the presentation through the "Events and Presentations" section on Moderna's investor website at investors.modernatx.com. The webcast recording will remain available on the company's website for a minimum of 30 days after the presentation.
FAQ
What is the current stock price of Moderna (MRNA)?
What is the market cap of Moderna (MRNA)?
